It will then be standard practice to publish the agendas at the start of each meeting and the minutes after their adoption the following month.
The European Medicines Agency (EMA) is publishing, for the first time, the agendas of the Committee for Medicinal Products for Human Use (CHMP), the Committee for Medicinal Products for Veterinary Use (CVMP) and the Committee for Advanced Therapies (CAT). The minutes of each of these meetings held in December will be published once they have been adopted by the relevant Committee at its meeting in January. It will then be standard practice to publish the agendas at the start of each meeting and the minutes after their adoption the following month.
This follows last week’s Management Board meeting, which cleared the way for the publication of the agendas and minutes of these three remaining EMA scientific committees. It is the final step of a process launched by the Agency in July 2012 that has already been implemented for its four other scientific committees.
“Openness of our operations is one of my key objectives. As part of this, we promised in July 2012 to start publishing agendas and minutes of all seven of our scientific committees by the end of 2013, and we are now delivering on this objective. Achieving our plan for all committees, including those giving recommendations on the marketing authorisation of medicines, the CHMP and CVMP, is a major milestone in this transparency initiative,” said Guido Rasi, Executive Director of the EMA.
“We see transparency as a priority as it is the basis for public confidence and trust in the Agency and the European Union system for the evaluation of medicines,” he added.
The Agency started publishing the agendas and minutes of its scientific committee meetings with the Pediatric Committee (PDCO) and the Pharmacovigilance Risk Assessment Committee (PRAC) in July 2012, followed by the Committee for Orphan Medicinal Products (COMP) in September 2012 and the Committee on Herbal Medicinal Products (HMPC) in September 2013.
Notes
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.